ROCKVILLE, Md., Nov. 14, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. The offering is subject to market […]
— Completed Enrollment of Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection (CDI), Antibiotic-Associated Diarrhea (AAD) and the Emergence of Antibiotic-Resistant Organisms — — Awarded Research Contract from Centers for Disease Control and Prevention to Determine SYN-004’s (ribaxamase) Ability to Prevent Antibiotic-Resistance in the Gut Microbiome — — Conference Call Today,
— Funding to Support Ongoing Phase 2b Study to Determine SYN-004’s (ribaxamase) Ability to Prevent the Emergence of Antibiotic-Resistance in the Gut Microbiome of Study Participants — ROCKVILLE, Md., Oct. 6, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific
— Top-line Results Anticipated in the First Quarter of 2017 — ROCKVILLE, Md., Sept. 20, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, announced today that following the completion of a previously planned interim analysis by an
— FDA Provides Company with Recommendation and Guidance for Clinical Study Design for Phase 2b/3 Adaptive Trial — ROCKVILLE, Md., Aug. 2, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, announced today the completion of an End of
— First Granted Patent in Europe Directly Related to Ribaxamase, intended to Prevent C. difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Organisms — ROCKVILLE, Md., July 12, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome announced today that the European Patent
— Ribaxamase Designed for the Prevention of C. difficile Infection, Antibiotic-Associated Diarrhea & the Emergence of Antibiotic-Resistant Organisms — — Oral Presentation Planned for ANAEROBE 2016 — ROCKVILLE, Md., July 7, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific
— Phase 2 Clinical Trials Demonstrate Potential of SYN-010 to Reduce Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores without Severe Adverse Events in IBS-C Patients — — Results from Separate PK Study Demonstrate SYN-010 Avoids the Stomach and Releases Throughout the GI Tract in Healthy Volunteers — — Mark
— Mark Pimentel, MD, FRCP(C) to Review IBS-C Patient Data from Two SYN-010 Phase 2 Clinical Trials — — Conference Call Scheduled on Monday, May 23, 2016, at 8:30 a.m. (EDT) — ROCKVILLE, Md., May 17, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the
— SYN-004 Degraded IV Ceftriaxone in the Presence of a Proton Pump Inhibitor in the Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream — — Two Poster Presentations Planned for ASM Microbe 2016, Including Detailed Data from Two SYN-004 Phase 2a Open-Label Clinical Trials — ROCKVILLE, Md., May16, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE
